1.
|
Phase: Phase IV Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: CWRU-CHIR-1899, CHIR-MA-99-01, CWRU-010002, NCI-G00-1875, NCT00006864
|
|
2.
|
Phase: Phase IV Type: Natural history/Epidemiology Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A6181203, DARENCA STUDY 2, NCT01339962
|
|
3.
|
Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AIS-1061-9320, NCI-V95-0689
|
|
4.
|
Phase: Phase III, Phase II Type: Treatment Status: Closed Age: under 75 Sponsor: Protocol IDs: CNR-9505, EU-95023
|
|
5.
|
Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 to 79 Sponsor: Protocol IDs: FRE-FNCLCC-95009, EU-96026
|
|
6.
|
Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 16 and over Sponsor: Protocol IDs: NCI-C87-0001, AECM-8706153, CHNMC-COH-7077, CMGH-8756-S-87A, CWRCC-0987188, DUMC-7988710, FCCC-88982, IDB-MGC-RENAL/RAND, JHOC-87092507, MDA-DM-87059, UAC-345, UCCRC-4998, UPCC-1887, UUMC-2056, VRCC-CHRMS-8831, WSU-C-70387, YALE-HIC-4454, C87-0001
|
|
7.
|
Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 16 and over Sponsor: Protocol IDs: NCI-C87-0002, AECM-8706152, CHNMC-COH-7075, CMGH-8755-S-87A, CWRCC-0787137, DUMC-7958710, IDB-MGC-MEL/RAND, JHOC-87092508, MDA-DM-87056, UAC-343, UCCRC-4985, UKMC-8800110, UPCC-1687, UUMC-2055, VRCC-CHRMS-8832, WSU-C-70487, YALE-HIC-4455, C87-0002
|
|
8.
|
Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 to 70 Sponsor: Protocol IDs: UCCRC-4973A, NCI-V87-0310
|
|
9.
|
Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 to 70 Sponsor: Protocol IDs: UCCRC-4973B, NCI-V87-0311
|
|
10.
|
Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 to 70 Sponsor: Protocol IDs: UCCRC-4973C, NCI-V87-0312
|
|
11.
|
Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 21 to 70 Sponsor: Protocol IDs: NYH-1088-350CRC, NCI-V88-0417
|
|
12.
|
Phase: Phase III, Phase II Type: Treatment Status: Completed Age: Under 30 Sponsor: NCI Protocol IDs: COG-AHOD0121, NCT00070187, AHOD0121
|
|
13.
|
Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: IL2NHL03, UCLA-0302013, CHIR-IL2NHL03-A01, NCT00045877
|
|
14.
|
Phase: Phase III Type: Treatment Status: Closed Age: not over 55 Sponsor: Protocol IDs: FHCRC-701.1, NCI-V94-0401
|
|
15.
|
Phase: Phase III Type: Treatment Status: Completed Age: 16 to 60 Sponsor: NCI Protocol IDs: SWOG-9328, E-S9328
|
|
16.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Protocol IDs: PCI-9430, NCI-V94-0493
|
|
17.
|
Phase: Phase III Type: Treatment Status: Completed Age: Under 22 Sponsor: NCI Protocol IDs: COG-2961, CCG-2961, NCT00002798
|
|
18.
|
Phase: Phase III Type: Treatment Status: Completed Age: 10 to 70 Sponsor: NCI, Other Protocol IDs: ID95-196, P30CA016672, MDA-ID-95196, MDA-DM-95196, NCI-G96-1089, CDR0000065188, NCT00002882
|
|
19.
|
Phase: Phase III Type: Treatment Status: Completed Age: Over 25 Sponsor: Other Protocol IDs: CDR0000065406, RPCI-DS-96-48, NCI-G97-1152, NCT00002945
|
|
20.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: MAXIM-US-M01, NCI-V98-1382
|
|
21.
|
Phase: Phase III Type: Treatment Status: Completed Age: 60 and over Sponsor: NCI, Other Protocol IDs: CDR0000066022, U10CA031946, CLB-9720, CALGB-9720, NCT00003190
|
|
22.
|
Phase: Phase III Type: Treatment Status: Closed Age: Any age Sponsor: NCI Protocol IDs: JHOC-97080106, JHOC-9726, NCI-V98-1453, NCT00003414
|
|
23.
|
Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: CCCGHS-NCI-T98-0085, NCI-T98-0085, NCI-99-C-0051B, T98-0085, NCT00019682
|
|
24.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MAXIM-MP-MA-0201, CWRU-MAXI-1998, NCT00003991
|
|
25.
|
Phase: Phase III Type: Treatment Status: Closed Age: 15 to 60 Sponsor: Other Protocol IDs: CDR0000067356, EORTC-06991, GIMEMA-EORTC-06991, NCT00004128
|